Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly

J. Fattouch, C. Di Bonaventura, S. Casciato, F. Bonini, S. Petrucci, L. Lapenta, M. Manfredi, M. Prencipe, A. T. Giallonardo

Research output: Contribution to journalArticle

Abstract

Background-Status epilepticus is a condition of prolonged/repetitive seizures that often occurs in the elderly. Treatment in the elderly can be complicated by serious side effects associated with traditional drugs. Objective-The aim of this pilot study was to evaluate the short-term efficacy/safety of intravenously administered LEV (IVLEV) as the treatment of choice for SE in the elderly. Methods-We enrolled nine elderly patients (five female/four male; median age 78 years) with SE. Two patients had a previous diagnosis of epilepsy; in the remaining seven, SE was symptomatic. SE was convulsive in five and non-convulsive in four. All the patients presented concomitant medical conditions (arrhythmias/respiratory distress/hepatic diseases). As the traditional therapy for SE was considered unsafe, IVLEV was used as first-line therapy (loading dose of 1500 mg/100 ml/15 min, mean maintenance daily dose of 2500 mg/24 h) administered during video-EEG monitoring. Results/conclusions-In all the patients but one, IVLEV was effective in the treatment of SE and determined either the disappearance of (7/8), or significant reduction in (1/8), epileptic activity; no patient relapsed in the subsequent 24 h. No adverse events or changes in the ECG/laboratory parameters were observed. These data suggest that IVLEV may be an effective/safe treatment for SE in the elderly.

Original languageEnglish
Pages (from-to)418-421
Number of pages4
JournalActa Neurologica Scandinavica
Volume121
Issue number6
DOIs
Publication statusPublished - 2010

Fingerprint

etiracetam
Status Epilepticus
Therapeutics
Cardiac Arrhythmias
Electroencephalography
Epilepsy
Electrocardiography
Seizures
Maintenance

Keywords

  • Elderly
  • Intravenous Levetiracetam
  • Status epilepticus

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Fattouch, J., Di Bonaventura, C., Casciato, S., Bonini, F., Petrucci, S., Lapenta, L., ... Giallonardo, A. T. (2010). Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly. Acta Neurologica Scandinavica, 121(6), 418-421. https://doi.org/10.1111/j.1600-0404.2010.01351.x

Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly. / Fattouch, J.; Di Bonaventura, C.; Casciato, S.; Bonini, F.; Petrucci, S.; Lapenta, L.; Manfredi, M.; Prencipe, M.; Giallonardo, A. T.

In: Acta Neurologica Scandinavica, Vol. 121, No. 6, 2010, p. 418-421.

Research output: Contribution to journalArticle

Fattouch, J, Di Bonaventura, C, Casciato, S, Bonini, F, Petrucci, S, Lapenta, L, Manfredi, M, Prencipe, M & Giallonardo, AT 2010, 'Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly', Acta Neurologica Scandinavica, vol. 121, no. 6, pp. 418-421. https://doi.org/10.1111/j.1600-0404.2010.01351.x
Fattouch, J. ; Di Bonaventura, C. ; Casciato, S. ; Bonini, F. ; Petrucci, S. ; Lapenta, L. ; Manfredi, M. ; Prencipe, M. ; Giallonardo, A. T. / Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly. In: Acta Neurologica Scandinavica. 2010 ; Vol. 121, No. 6. pp. 418-421.
@article{c13e3439234e420f97883aa63ee16c6f,
title = "Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly",
abstract = "Background-Status epilepticus is a condition of prolonged/repetitive seizures that often occurs in the elderly. Treatment in the elderly can be complicated by serious side effects associated with traditional drugs. Objective-The aim of this pilot study was to evaluate the short-term efficacy/safety of intravenously administered LEV (IVLEV) as the treatment of choice for SE in the elderly. Methods-We enrolled nine elderly patients (five female/four male; median age 78 years) with SE. Two patients had a previous diagnosis of epilepsy; in the remaining seven, SE was symptomatic. SE was convulsive in five and non-convulsive in four. All the patients presented concomitant medical conditions (arrhythmias/respiratory distress/hepatic diseases). As the traditional therapy for SE was considered unsafe, IVLEV was used as first-line therapy (loading dose of 1500 mg/100 ml/15 min, mean maintenance daily dose of 2500 mg/24 h) administered during video-EEG monitoring. Results/conclusions-In all the patients but one, IVLEV was effective in the treatment of SE and determined either the disappearance of (7/8), or significant reduction in (1/8), epileptic activity; no patient relapsed in the subsequent 24 h. No adverse events or changes in the ECG/laboratory parameters were observed. These data suggest that IVLEV may be an effective/safe treatment for SE in the elderly.",
keywords = "Elderly, Intravenous Levetiracetam, Status epilepticus",
author = "J. Fattouch and {Di Bonaventura}, C. and S. Casciato and F. Bonini and S. Petrucci and L. Lapenta and M. Manfredi and M. Prencipe and Giallonardo, {A. T.}",
year = "2010",
doi = "10.1111/j.1600-0404.2010.01351.x",
language = "English",
volume = "121",
pages = "418--421",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley Blackwell",
number = "6",

}

TY - JOUR

T1 - Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly

AU - Fattouch, J.

AU - Di Bonaventura, C.

AU - Casciato, S.

AU - Bonini, F.

AU - Petrucci, S.

AU - Lapenta, L.

AU - Manfredi, M.

AU - Prencipe, M.

AU - Giallonardo, A. T.

PY - 2010

Y1 - 2010

N2 - Background-Status epilepticus is a condition of prolonged/repetitive seizures that often occurs in the elderly. Treatment in the elderly can be complicated by serious side effects associated with traditional drugs. Objective-The aim of this pilot study was to evaluate the short-term efficacy/safety of intravenously administered LEV (IVLEV) as the treatment of choice for SE in the elderly. Methods-We enrolled nine elderly patients (five female/four male; median age 78 years) with SE. Two patients had a previous diagnosis of epilepsy; in the remaining seven, SE was symptomatic. SE was convulsive in five and non-convulsive in four. All the patients presented concomitant medical conditions (arrhythmias/respiratory distress/hepatic diseases). As the traditional therapy for SE was considered unsafe, IVLEV was used as first-line therapy (loading dose of 1500 mg/100 ml/15 min, mean maintenance daily dose of 2500 mg/24 h) administered during video-EEG monitoring. Results/conclusions-In all the patients but one, IVLEV was effective in the treatment of SE and determined either the disappearance of (7/8), or significant reduction in (1/8), epileptic activity; no patient relapsed in the subsequent 24 h. No adverse events or changes in the ECG/laboratory parameters were observed. These data suggest that IVLEV may be an effective/safe treatment for SE in the elderly.

AB - Background-Status epilepticus is a condition of prolonged/repetitive seizures that often occurs in the elderly. Treatment in the elderly can be complicated by serious side effects associated with traditional drugs. Objective-The aim of this pilot study was to evaluate the short-term efficacy/safety of intravenously administered LEV (IVLEV) as the treatment of choice for SE in the elderly. Methods-We enrolled nine elderly patients (five female/four male; median age 78 years) with SE. Two patients had a previous diagnosis of epilepsy; in the remaining seven, SE was symptomatic. SE was convulsive in five and non-convulsive in four. All the patients presented concomitant medical conditions (arrhythmias/respiratory distress/hepatic diseases). As the traditional therapy for SE was considered unsafe, IVLEV was used as first-line therapy (loading dose of 1500 mg/100 ml/15 min, mean maintenance daily dose of 2500 mg/24 h) administered during video-EEG monitoring. Results/conclusions-In all the patients but one, IVLEV was effective in the treatment of SE and determined either the disappearance of (7/8), or significant reduction in (1/8), epileptic activity; no patient relapsed in the subsequent 24 h. No adverse events or changes in the ECG/laboratory parameters were observed. These data suggest that IVLEV may be an effective/safe treatment for SE in the elderly.

KW - Elderly

KW - Intravenous Levetiracetam

KW - Status epilepticus

UR - http://www.scopus.com/inward/record.url?scp=77952653328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952653328&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0404.2010.01351.x

DO - 10.1111/j.1600-0404.2010.01351.x

M3 - Article

C2 - 20578996

AN - SCOPUS:77952653328

VL - 121

SP - 418

EP - 421

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 6

ER -